TFF Pharmaceuticals Management
Management criteria checks 0/4
TFF Pharmaceuticals' CEO is Harlan Weisman, appointed in Dec 2022, has a tenure of 1.58 years. total yearly compensation is $2.08M, comprised of 26.5% salary and 73.5% bonuses, including company stock and options. directly owns 1.05% of the company’s shares, worth €53.98K. The average tenure of the management team and the board of directors is 1.6 years and 2.9 years respectively.
Key information
Harlan Weisman
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 26.5% |
| CEO tenure | 1.6yrs |
| CEO ownership | 1.1% |
| Management average tenure | 1.6yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$20m |
| Dec 31 2023 | US$2m | US$550k | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$594k | US$42k | -US$32m |
| Sep 30 2022 | n/a | n/a | -US$34m |
| Jun 30 2022 | n/a | n/a | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$32m |
| Dec 31 2021 | US$40k | n/a | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$22m |
| Dec 31 2020 | US$241k | n/a | -US$19m |
| Sep 30 2020 | n/a | n/a | -US$41m |
| Jun 30 2020 | n/a | n/a | -US$39m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$216k | n/a | -US$37m |
Compensation vs Market: Harlan's total compensation ($USD2.08M) is above average for companies of similar size in the German market ($USD533.87K).
Compensation vs Earnings: Harlan's compensation has increased whilst the company is unprofitable.
CEO
Harlan Weisman (72 yo)
1.6yrs
Tenure
US$2,076,038
Compensation
Dr. Harlan F. Weisman M.D. is Operating Partner of CR Group L.P. Dr. Weisman was Senior Advisor of CR Group L.P. from 2012. Dr. Weisman is Clinical Advisor of Protagonist Therapeutics, Inc. Dr. Weisman joi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.6yrs | US$2.08m | 1.05% $ 54.6k | |
| CFO, Treasurer & Secretary | 6.5yrs | US$469.07k | 0.046% $ 2.4k | |
| Chief Medical Officer | 1.5yrs | US$865.13k | 0.17% $ 9.1k |
1.6yrs
Average Tenure
60yo
Average Age
Experienced Management: 0K30's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.6yrs | US$2.08m | 1.05% $ 54.6k | |
| Independent Director | 6.5yrs | US$144.53k | 0.072% $ 3.8k | |
| Independent Director | 5.6yrs | US$67.88k | 0.046% $ 2.4k | |
| Chairman of the Scientific Advisory Board and Senior Research & Development Advisor | 1.5yrs | no data | no data | |
| Independent Director | less than a year | US$41.85k | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | 2.3yrs | US$70.92k | 0.026% $ 1.3k | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data |
2.9yrs
Average Tenure
52yo
Average Age
Experienced Board: 0K30's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.